U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Proximal tubulopathy

MedGen UID:
326534
Concept ID:
C1839603
Disease or Syndrome; Finding
Synonyms: Proximal renal tubule defect; Proximal renal tubulopathy; Renal proximal tubule defect
 
HPO: HP:0000114

Definition

Dysfunction of the proximal tubule, which is the portion of the duct system of the nephron of the kidney which leads from Bowman's capsule to the loop of Henle. [from HPO]

Conditions with this feature

Hereditary fructosuria
MedGen UID:
42105
Concept ID:
C0016751
Disease or Syndrome
Following dietary exposure to fructose, sucrose, or sorbitol, untreated hereditary fructose intolerance (HFI) is characterized by metabolic disturbances (hypoglycemia, lactic acidemia, hypophosphatemia, hyperuricemia, hypermagnesemia, hyperalaninemia) and clinical findings (nausea, vomiting, and abdominal distress; chronic growth restriction / failure to thrive). While untreated HFI typically first manifested when fructose- and sucrose-containing foods were introduced in the course of weaning young infants from breast milk, it is now presenting earlier, due to the addition of fructose-containing nutrients in infant formulas. If the infant ingests large quantities of fructose, the infant may acutely develop lethargy, seizures, and/or progressive coma. Untreated HFI may result in renal and hepatic failure. If identified and treated before permanent organ injury occurs, individuals with HFI can experience a normal quality of life and life expectancy.
Familial hypokalemic alkalosis, Gullner type
MedGen UID:
78677
Concept ID:
C0268444
Disease or Syndrome
Multiple acyl-CoA dehydrogenase deficiency
MedGen UID:
75696
Concept ID:
C0268596
Disease or Syndrome
Multiple acyl-CoA dehydrogenase deficiency (MADD) represents a clinical spectrum in which presentations can be divided into type I (neonatal onset with congenital anomalies), type II (neonatal onset without congenital anomalies), and type III (late onset). Individuals with type I or II MADD typically become symptomatic in the neonatal period with severe metabolic acidosis, which may be accompanied by profound hypoglycemia and hyperammonemia. Many affected individuals die in the newborn period despite metabolic treatment. In those who survive the neonatal period, recurrent metabolic decompensation resembling Reye syndrome and the development of hypertrophic cardiomyopathy can occur. Congenital anomalies may include dysmorphic facial features, large cystic kidneys, hypospadias and chordee in males, and neuronal migration defects (heterotopias) on brain MRI. Individuals with type III MADD, the most common presentation, can present from infancy to adulthood. The most common symptoms are muscle weakness, exercise intolerance, and/or muscle pain, although metabolic decompensation with episodes of rhabdomyolysis can also be seen. Rarely, individuals with late-onset MADD (type III) may develop severe sensory neuropathy in addition to proximal myopathy.
PMM2-congenital disorder of glycosylation
MedGen UID:
138111
Concept ID:
C0349653
Disease or Syndrome
PMM2-CDG, the most common of a group of disorders of abnormal glycosylation of N-linked oligosaccharides, is divided into three clinical stages: infantile multisystem, late-infantile and childhood ataxia–intellectual disability, and adult stable disability. The clinical manifestations and course are highly variable, ranging from infants who die in the first year of life to mildly affected adults. Clinical findings tend to be similar in sibs. In the infantile multisystem presentation, infants show axial hypotonia, hyporeflexia, esotropia, and developmental delay. Feeding problems, vomiting, faltering growth, and developmental delay are frequently seen. Subcutaneous fat may be excessive over the buttocks and suprapubic region. Two distinct clinical courses are observed: (1) a nonfatal neurologic course with faltering growth, strabismus, developmental delay, cerebellar hypoplasia, and hepatopathy in infancy followed by neuropathy and retinitis pigmentosa in the first or second decade; and (2) a more severe neurologic-multivisceral course with approximately 20% mortality in the first year of life. The late-infantile and childhood ataxia–intellectual disability stage, which begins between ages three and ten years, is characterized by hypotonia, ataxia, severely delayed language and motor development, inability to walk, and IQ of 40 to 70; other findings include seizures, stroke-like episodes or transient unilateral loss of function, coagulopathy, retinitis pigmentosa, joint contractures, and skeletal deformities. In the adult stable disability stage, intellectual ability is stable; peripheral neuropathy is variable, progressive retinitis pigmentosa and myopia are seen, thoracic and spinal deformities with osteoporosis worsen, and premature aging is observed; females may lack secondary sexual development and males may exhibit decreased testicular volume. Hypogonadotropic hypogonadism and coagulopathy may occur. The risk for deep venous thrombosis is increased.
X-linked recessive nephrolithiasis with renal failure
MedGen UID:
96047
Concept ID:
C0403720
Disease or Syndrome
X-linked recessive nephrolithiasis with renal failure (XRN) is a form of X-linked hypercalciuric nephrolithiasis, which comprises a group of disorders characterized by proximal renal tubular reabsorptive failure, hypercalciuria, nephrolithiasis, and renal insufficiency. These disorders have also been referred to as the 'Dent disease complex' (Scheinman, 1998; Gambaro et al., 2004). For a general discussion of Dent disease, see 300009.
Proteinuria, low molecular weight, with hypercalciuria and nephrocalcinosis
MedGen UID:
333426
Concept ID:
C1839874
Disease or Syndrome
Low molecular weight proteinuria with hypercalciuria and nephrocalcinosis is a form of X-linked hypercalciuric nephrocalcinosis, a group of disorders characterized by proximal renal tubular reabsorptive failure, hypercalciuria, nephrocalcinosis, and renal insufficiency. These disorders have also been referred to as the 'Dent disease complex' (Scheinman, 1998; Gambaro et al., 2004). For a general discussion of Dent disease, see 300009.
Dent disease type 2
MedGen UID:
336867
Concept ID:
C1845167
Disease or Syndrome
Dent disease, an X-linked disorder of proximal renal tubular dysfunction, is characterized by low molecular weight (LMW) proteinuria, hypercalciuria, and at least one additional finding including nephrocalcinosis, nephrolithiasis, hematuria, hypophosphatemia, chronic kidney disease (CKD), and evidence of X-linked inheritance. Males younger than age ten years may manifest only LMW proteinuria and/or hypercalciuria, which are usually asymptomatic. Thirty to 80% of affected males develop end-stage renal disease (ESRD) between ages 30 and 50 years; in some instances ESRD does not develop until the sixth decade of life or later. The disease may also be accompanied by rickets or osteomalacia, growth restriction, and short stature. Disease severity can vary within the same family. Males with Dent disease 2 (caused by pathogenic variants in OCRL) may also have mild intellectual disability, cataracts, and/or elevated muscle enzymes. Due to random X-chromosome inactivation, some female carriers may manifest hypercalciuria and, rarely, renal calculi and moderate LMW proteinuria. Females rarely develop CKD.
Hypophosphatemic rickets, X-linked recessive
MedGen UID:
335115
Concept ID:
C1845168
Disease or Syndrome
X-linked recessive hypophosphatemic rickets (XLHRR) is a form of X-linked hypercalciuric nephrolithiasis, which comprises a group of disorders characterized by proximal renal tubular reabsorptive failure, hypercalciuria, nephrocalcinosis, and renal insufficiency. These disorders have also been referred to as the 'Dent disease complex' (Scheinman, 1998; Gambaro et al., 2004). For a general discussion of Dent disease, see 300009.
Dent disease type 1
MedGen UID:
336322
Concept ID:
C1848336
Disease or Syndrome
Dent disease, an X-linked disorder of proximal renal tubular dysfunction, is characterized by low molecular weight (LMW) proteinuria, hypercalciuria, and at least one additional finding including nephrocalcinosis, nephrolithiasis, hematuria, hypophosphatemia, chronic kidney disease (CKD), and evidence of X-linked inheritance. Males younger than age ten years may manifest only LMW proteinuria and/or hypercalciuria, which are usually asymptomatic. Thirty to 80% of affected males develop end-stage renal disease (ESRD) between ages 30 and 50 years; in some instances ESRD does not develop until the sixth decade of life or later. The disease may also be accompanied by rickets or osteomalacia, growth restriction, and short stature. Disease severity can vary within the same family. Males with Dent disease 2 (caused by pathogenic variants in OCRL) may also have mild intellectual disability, cataracts, and/or elevated muscle enzymes. Due to random X-chromosome inactivation, some female carriers may manifest hypercalciuria and, rarely, renal calculi and moderate LMW proteinuria. Females rarely develop CKD.
MPI-congenital disorder of glycosylation
MedGen UID:
400692
Concept ID:
C1865145
Disease or Syndrome
Congenital disorders of glycosylation (CDGs) are a genetically heterogeneous group of autosomal recessive disorders caused by enzymatic defects in the synthesis and processing of asparagine (N)-linked glycans or oligosaccharides on glycoproteins. Type I CDGs comprise defects in the assembly of the dolichol lipid-linked oligosaccharide (LLO) chain and its transfer to the nascent protein. These disorders can be identified by a characteristic abnormal isoelectric focusing profile of plasma transferrin (Leroy, 2006). For a discussion of the classification of CDGs, see CDG1A (212065). CDG Ib is clinically distinct from most other CDGs by the lack of significant central nervous system involvement. The predominant symptoms are chronic diarrhea with failure to thrive and protein-losing enteropathy with coagulopathy. Some patients develop hepatic fibrosis. CDG Ib is also different from other CDGs in that it can be treated effectively with oral mannose supplementation, but can be fatal if untreated (Marquardt and Denecke, 2003). Thus, CDG Ib should be considered in the differential diagnosis of patients with unexplained hypoglycemia, chronic diarrhea, liver disease, or coagulopathy in order to allow early diagnosis and effective therapy (Vuillaumier-Barrot et al., 2002) Freeze and Aebi (1999) reviewed CDG Ib and CDG Ic (603147). Marques-da-Silva et al. (2017) systematically reviewed the literature concerning liver involvement in CDG.
Mitochondrial DNA depletion syndrome 8a
MedGen UID:
412815
Concept ID:
C2749861
Disease or Syndrome
Four phenotypes comprise the RRM2B mitochondrial DNA maintenance defects (RRM2B-MDMDs): RRM2B encephalomyopathic MDMD, the most severe phenotype, usually manifesting shortly after birth as hypotonia, poor feeding, and faltering growth requiring hospitalization. Subsequent assessments are likely to reveal multisystem involvement including sensorineural hearing loss, renal tubulopathy, and respiratory failure. Autosomal dominant progressive external ophthalmoplegia (adPEO), typically adult onset; other manifestations can include ptosis, bulbar dysfunction, fatigue, and muscle weakness. RRM2B autosomal recessive progressive external ophthalmoplegia (arPEO), a typically childhood-onset predominantly myopathic phenotype of PEO, ptosis, proximal muscle weakness, and bulbar dysfunction. RRM2B mitochondrial neurogastrointestinal encephalopathy (MNGIE)-like, characterized by progressive ptosis, ophthalmoplegia, gastrointestinal dysmotility, cachexia, and peripheral neuropathy. To date, 78 individuals from 52 families with a molecularly confirmed RRM2B-MDMD have been reported.
Fanconi renotubular syndrome 2
MedGen UID:
462002
Concept ID:
C3150652
Disease or Syndrome
Any Fanconi syndrome in which the cause of the disease is a mutation in the SLC34A1 gene.
Proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome
MedGen UID:
463309
Concept ID:
C3151959
Disease or Syndrome
Proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome is characterized by onset of proximal tubulopathy in the first year of life, followed by progressive development during childhood of skin anomalies (erythrocyanosis and abnormal pigmentation), blindness, osteoporosis, cerebellar ataxia, mitochondrial myopathy, deafness and diabetes mellitus.
COG6-congenital disorder of glycosylation
MedGen UID:
766144
Concept ID:
C3553230
Disease or Syndrome
CDG2L is an autosomal recessive multisystem disorder apparent from birth or early infancy. It is characterized by poor growth, gastrointestinal and liver abnormalities, delayed psychomotor development, hypotonia, recurrent infections, hematologic abnormalities, increased bleeding tendency, and hyperhidrosis or hyperkeratosis. More variable features include nonspecific dysmorphic facial features and cardiac septal defects. The disorder often results in death in infancy or the first years of life (summary by Rymen et al., 2015). For a general discussion of CDGs, see CDG1A (212065) and CDG2A (212066).
Combined oxidative phosphorylation deficiency 55
MedGen UID:
1806598
Concept ID:
C5676915
Disease or Syndrome
Combined oxidative phosphorylation deficiency-55 (COXPD55) is characterized by global developmental delay, hypotonia, short stature, and impaired intellectual development with speech disabilities in childhood. Indolent progressive external ophthalmoplegia phenotype has been described in 1 patient (summary by Olahova et al., 2021). For a discussion of genetic heterogeneity of combined oxidative phosphorylation deficiency, see COXPD1 (609060).

Professional guidelines

PubMed

Overduin RJ, Grünert SC, Besouw MTP, Bolhuis MS, Groen J, Schreuder AB, Woidy M, Murko S, Santer R, Derks TGJ
J Inherit Metab Dis 2024 Sep;47(5):1018-1027. Epub 2024 May 27 doi: 10.1002/jimd.12752. PMID: 38802119
Bonora S, Calcagno A, Trentalange A, Di Perri G
Expert Opin Pharmacother 2016;17(3):409-19. doi: 10.1517/14656566.2016.1129401. PMID: 26642079
Stokes MB, Valeri AM, Herlitz L, Khan AM, Siegel DS, Markowitz GS, D'Agati VD
J Am Soc Nephrol 2016 May;27(5):1555-65. Epub 2015 Sep 15 doi: 10.1681/ASN.2015020185. PMID: 26374607Free PMC Article

Recent clinical studies

Etiology

Larcher R, Bargnoux AS, Badiou S, Besnard N, Brunot V, Daubin D, Platon L, Benomar R, Amalric M, Dupuy AM, Klouche K, Cristol JP
Ren Fail 2023;45(2):2292152. Epub 2023 Dec 11 doi: 10.1080/0886022X.2023.2292152. PMID: 38078385Free PMC Article
Kousios A, Blakey S, Moran L, Atta M, Charif R, Duncan N, Smith A, Tam FWK, Levy JB, Chaidos A, Roufosse C
Nephrol Dial Transplant 2023 Oct 31;38(11):2576-2588. doi: 10.1093/ndt/gfad085. PMID: 37120733Free PMC Article
Gianesello L, Del Prete D, Ceol M, Priante G, Calò LA, Anglani F
Gene 2020 Jul 15;747:144662. Epub 2020 Apr 11 doi: 10.1016/j.gene.2020.144662. PMID: 32289351Free PMC Article
Perazella MA
Clin J Am Soc Nephrol 2018 Dec 7;13(12):1897-1908. Epub 2018 Apr 5 doi: 10.2215/CJN.00150118. PMID: 29622670Free PMC Article
Stokes MB, Valeri AM, Herlitz L, Khan AM, Siegel DS, Markowitz GS, D'Agati VD
J Am Soc Nephrol 2016 May;27(5):1555-65. Epub 2015 Sep 15 doi: 10.1681/ASN.2015020185. PMID: 26374607Free PMC Article

Diagnosis

Nasr SH, Sirac C, Leung N, Bridoux F
Kidney Int 2024 Aug;106(2):201-213. Epub 2024 May 7 doi: 10.1016/j.kint.2024.02.027. PMID: 38723749
Nasr SH, Kudose S, Javaugue V, Harel S, Said SM, Pascal V, Stokes MB, Vrana JA, Dasari S, Theis JD, Osuchukwu GA, Sathick IJ, Das A, Kashkouli A, Suchin EJ, Liss Y, Suldan Z, Verine J, Arnulf B, Talbot A, Sethi S, Zaidan M, Goujon JM, Valeri AM, Mcphail ED, Sirac C, Leung N, Bridoux F, D'Agati VD
Kidney Int 2023 Mar;103(3):616-626. Epub 2022 Dec 26 doi: 10.1016/j.kint.2022.11.026. PMID: 36581019
Sy-Go JPT, Herrmann SM, Seshan SV
Adv Chronic Kidney Dis 2022 Mar;29(2):86-102.e1. doi: 10.1053/j.ackd.2022.01.004. PMID: 35817530
Sethi S, Rajkumar SV, D'Agati VD
J Am Soc Nephrol 2018 Jul;29(7):1810-1823. Epub 2018 Apr 27 doi: 10.1681/ASN.2017121319. PMID: 29703839Free PMC Article
Gupta V, El Ters M, Kashani K, Leung N, Nasr SH
J Am Soc Nephrol 2015 Mar;26(3):525-9. Epub 2014 Sep 4 doi: 10.1681/ASN.2014050509. PMID: 25190731Free PMC Article

Therapy

Nasr SH, Sirac C, Leung N, Bridoux F
Kidney Int 2024 Aug;106(2):201-213. Epub 2024 May 7 doi: 10.1016/j.kint.2024.02.027. PMID: 38723749
Kudose S, Lipton M, Jain NG, D'Agati VD
Kidney Int 2022 Mar;101(3):653. doi: 10.1016/j.kint.2021.08.005. PMID: 35190045
Perazella MA
Clin J Am Soc Nephrol 2018 Dec 7;13(12):1897-1908. Epub 2018 Apr 5 doi: 10.2215/CJN.00150118. PMID: 29622670Free PMC Article
Tozzi V
Antiviral Res 2010 Jan;85(1):190-200. Epub 2009 Sep 8 doi: 10.1016/j.antiviral.2009.09.001. PMID: 19744523
Phillips RS, Tyerman K, Al-Kassim MI, Picton S
Pediatr Hematol Oncol 2008 Mar;25(2):107-13. doi: 10.1080/08880010701885276. PMID: 18363176

Prognosis

Nasr SH, Sirac C, Leung N, Bridoux F
Kidney Int 2024 Aug;106(2):201-213. Epub 2024 May 7 doi: 10.1016/j.kint.2024.02.027. PMID: 38723749
Sethi S, Rajkumar SV, D'Agati VD
J Am Soc Nephrol 2018 Jul;29(7):1810-1823. Epub 2018 Apr 27 doi: 10.1681/ASN.2017121319. PMID: 29703839Free PMC Article
Gilbert RE
Diabetes 2017 Apr;66(4):791-800. doi: 10.2337/db16-0796. PMID: 28325740
van Berkel Y, Ludwig M, van Wijk JAE, Bökenkamp A
Pediatr Nephrol 2017 Oct;32(10):1851-1859. Epub 2016 Oct 18 doi: 10.1007/s00467-016-3499-x. PMID: 27757584Free PMC Article
Stokes MB, Valeri AM, Herlitz L, Khan AM, Siegel DS, Markowitz GS, D'Agati VD
J Am Soc Nephrol 2016 May;27(5):1555-65. Epub 2015 Sep 15 doi: 10.1681/ASN.2015020185. PMID: 26374607Free PMC Article

Clinical prediction guides

Wang X, Yu XJ, Wang SX, Zhou FD, Zhao MH
Ren Fail 2024 Dec;46(1):2283587. Epub 2024 Feb 19 doi: 10.1080/0886022X.2023.2283587. PMID: 38374684Free PMC Article
Larcher R, Bargnoux AS, Badiou S, Besnard N, Brunot V, Daubin D, Platon L, Benomar R, Amalric M, Dupuy AM, Klouche K, Cristol JP
Ren Fail 2023;45(2):2292152. Epub 2023 Dec 11 doi: 10.1080/0886022X.2023.2292152. PMID: 38078385Free PMC Article
Lerner G, Moradi S, Cohen-Bucay A, Chen H, Sanchorawala V, Gordon CE, Henderson JM
Clin Nephrol 2020 Apr;93(4):203-208. doi: 10.5414/CN109770. PMID: 31907143
Stokes MB, Valeri AM, Herlitz L, Khan AM, Siegel DS, Markowitz GS, D'Agati VD
J Am Soc Nephrol 2016 May;27(5):1555-65. Epub 2015 Sep 15 doi: 10.1681/ASN.2015020185. PMID: 26374607Free PMC Article
Tozzi V
Antiviral Res 2010 Jan;85(1):190-200. Epub 2009 Sep 8 doi: 10.1016/j.antiviral.2009.09.001. PMID: 19744523

Recent systematic reviews

Phillips RS, Tyerman K, Al-Kassim MI, Picton S
Pediatr Hematol Oncol 2008 Mar;25(2):107-13. doi: 10.1080/08880010701885276. PMID: 18363176

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...